Goldshield Grp PLC - Acquisition
05 June 2000 - 5:03PM
UK Regulatory
RNS Number:6522L
Goldshield Group PLC
5 June 2000
Acquisition of Nitrofurantoin Range for Portugal
The Directors of Goldshield Group PLC are pleased to
announce the acquisition of licenses, trademarks and know-
how for Portugal for Furadantin from Procter & Gamble
Pharmaceuticals, Inc. ("Procter & Gamble") for a cash
consideration of US $3.29 million payable in full on
completion. Sales of this product in Portugal for the 12
months to 30 April 2000 were US $1.19 million.
Furadantin is part of the Nitrofurantoin product range
and is used for the treatment of urinary infections.
On 20 September 1999 the Company announced the
acquisition of the Nitrofurantoin range of products
relating to several other European territories from
Procter & Gamble. Procter and Gamble will continue to
market the Nitrofurantoin products in the United States.
Ajit Patel, Chairman and Chief Executive of Goldshield
Group PLC, said:
"The Nitrofurantoin rights for Portugal complete our
European range for these products."
For Further Information Please Contact:
Goldshield Group plc
Ajit Patel, Chairman and Chief Executive
Tel: +44 (0) 20 8649 8500
Buchanan Communications Tel: + 44 (0) 20466 5000
Nicola How/Nicola Cronk
Notes to editors:
Goldshield Group plc: a profitable, British, marketing-
led, emerging pharmaceutical company based in Croydon,
Surrey, was founded in 1990, to sell healthcare and
pharmaceutical products internationally. In June 1998
Goldshield floated on the London Stock Exchange and
currently has a market capitalisation of around #250
million.
END
ACQEAPKAELKEEFE
Goldshield (LSE:GSD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Goldshield (LSE:GSD)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Goldshield Grp (London Stock Exchange): 0 recent articles
More Goldshield Grp PLC News Articles